In absence of head-to-head trials, the efficacy of the anti-TNF ADA, CZP, ETN, GOL, IFX and the available biosimilars for the treatment of RA has been evaluated by indirect comparison in several systematic reviews and meta-analyses (22). This evidence concerns the gene TNF and rheumatoid arthritis.